期刊文献+

心型脂肪酸结合蛋白在急性非ST抬高心肌梗死早期鉴别诊断中的价值 被引量:1

The Value of Heart-type Fatty Acid Binding Protein in the Differential Diagnosis of Patients with Acute non-ST Elevation Myocardial Infarction
下载PDF
导出
摘要 目的探讨心型游离脂肪酸结合蛋白在急性非ST抬高心肌梗死超早期(<6h)的应用价值。方法选取2009年6月至2012年3月我院就诊的106名NSTEMI患者,以冠状动脉造影结果、冠状动脉CTA结果作为最终诊断,入院即刻定性测定H-FABP及定量测定cTnI。结果在本研究入组的患者中,H-FABP、cTnI相比具有较好的敏感性和特异性;同时检测H-FABP与cTnI两项诊断NSTEMI,均有较高敏感性、特异性、阳性预测值、阴性预测值。结论 H-FABP可作为急性心肌损伤检测的一项快速、准确、敏感、特异的指标。 Objective To explore the application value of H-FABP in NSTEMI early diagnosis.Methods 106 NSTEMI patients in our hospital from 2009.3 to 2012.3 were selected with PCI,CTA results as the diagnostic criteria.Then H-FABP and cTnI were collected in early period of NSTEMI.Results Compared with cTnI,H-FABP showed higher sensitivity and specificity,and combining H-FABP with cTnI,the sensitivity,specificity,positive and negtive predictive values indicated the combination had the highest value in diagnosis of NSTEMI.Conclusion H-FABP is one of the most useful methods in the early diagnosis of NSTEMI.
作者 王红艳
出处 《中国医药指南》 2012年第30期19-20,共2页 Guide of China Medicine
关键词 心型游离脂肪酸结合蛋白 胸痛 冠心病 Heart type fatty acid binding protein(H-FABP) Chest pain Coronary heart disease
  • 相关文献

参考文献7

  • 1胡大一,孙艺红.心脏标志物检测的临床应用和进展[J].中国心血管病研究,2005,3(12):934-937. 被引量:41
  • 2Nakata T,Hashimoto A,Hase M,et al.Human heart-type fatty acid-binding protein as an early diagnostic and prognostic marker inacute coronary syndrome[J].Cardiology,2003,99(2):96-104.
  • 3陈莉莉,杨霏,郭小梅,等.快速检测心肌脂肪酸结合蛋白诊断早期心肌梗死[J].中华急救医学杂志,2005,14(11):934-937.
  • 4Umut C,Figen C,Bunyamin Y,et al.Heart-type fatty-acid bindingprotein can be a diagnostic marker in acute coronary syndromes[J].J National Med Asso,2006,98(7):1067-1070.
  • 5Cui lY,Zhang J,Hu XZ.Prognostic value of combination of heart-type fatty acid-binding protein and ischemia-modified albuminin patients with acute coronary syndromes and normal troponin Tvalues[J].J Clin Lab Anal,2009,23(1):14-18.
  • 6Komamura K,Sasaki T,Hanatani A,et al.Heart-type fatty acidbinding protein is a novel prognostic marker in patients with non-ischaemic dilated cardiomyopathy[J].Heart,2006,92(5):615-618.
  • 7Tanaka T,Sohmiya K,Kitaura Y,et al.Clinical evaluation of point-of-care-testing of heart-type fatty acid-binding protein(H-FABP)for the diagnosis of acute myocardial infarction[J].J Immunoassay[J]Immunochem,2006,27(3):225-238.

二级参考文献19

  • 1[15]Marumoto K, Hamada M, Hiwada K. Increased secretion of atrial and brain natriuretic peptides during acute myocardial ischemia induced by dynamic exercise in patients with angina pectoris. Clin Sci (Lond),1995, 88:551-556.
  • 2[16]Jerberg T, Lindahl B, Siegbahn A, et al. N-terminal pro brain natriuretic peptide in relation to inflammation,myocardial necrosis and the effects of an invasive strategy in unstable coronary artery disease. J Am Coll Cardial, 2003, 42:1909-1916.
  • 3[17]Sato Y, Yamada T, Taniguchi R, et al. Persistently increased serum concentrations of cardiac troponin t in patients with idiopathic dilated cardiomyopathy are predictive of adverse outcomes. Circulation,2001,103:369-374.
  • 4[18]Horwich TB, Patel J, MacLellan RW, et al. Cardiac troponin Ⅰ is associated with impaired hemodynamics,progressive left ventricular dysfunction, and increased mortality in advanced heart failure. Circulation,2003,108: 833-838.
  • 5[19]Venge P, Lagerqvist B, Diderholm E, et al. Clinical performance of three cardiac troponin assays in patients with unstable coronary artery disease (a FRISC Ⅱsubstudy). Am J Cardial, 2002,89:1035-1041.
  • 6[1]Panteghini M. Acute coronary syndrome. Biochemical strategies in the troponin era. Chest, 2002,122:1428-1435.
  • 7[2]Alpert JS, Thygesen K, Antman E,et al. Myocardial infarction redefined consensus document of the Joint European Society of Cardiology/Am college of cardiology committee for the redefinition of myocardial infarction. J Am Coll Cardiol, 2002,36: 959-969.
  • 8[3]Nomenclature and Criteria for Diagnosis of Ischemic Heart Disease. Report of the Joint International Society and Federation of Cardiology/World Health Organization Task Force on Standardization of Clinical Nomenclature. Circulation, 1979,59: 607-608.
  • 9[4]Panteghini M.Role and importance of biochemical markers in clinical cardiology. European Heart Journal,2004, 25:1187-1196.
  • 10[5]Wu AHB. National academy of clinical biochemistry standards of laboratory practice: recommendations for the uso of cardiac markers in coronary artery diseases. Clin Chem, 1999,45: 1104-1121.

共引文献40

同被引文献11

引证文献1

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部